Thursday, 21 October 2021

Tag Archives: ViiV

GSK long-acting HIV injection succeeds in study

GlaxoSmithKline’s prospective two-monthly two-drug injection to treat HIV was as effective as a monthly dose of the same regimen in maintaining viral suppression at 48 weeks in a late-stage study, the British drugmaker said. The long-acting needle-based combination of its drug cabotegravir and Janssen’s treatment rilpivirine met its main goal ...

Read More »